Prevention of Myopia Progression
MicroPineTM is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with significant eye damage including retinal detachment, choroidal and retinal atrophy and choroidal neovascularization, all of which can lead to permanent vision loss. In the US alone, there are more than 5 million children with myopia and many times more that number in Asia. Eyenovia’s delivery technology is particularly well-suited for this application, allowing children to easily self-administer medication while minimizing dose-related side effects and, through our smart technology, providing dosing reminders to help ensure the best possible outcome from treatment.
Unlike nearsightedness which we correct with glasses and laser eye surgery, myopic progression is a vision-threatening, back-of-the-eye disease characterized by uncontrolled stretching of the sclera and the retina which can lead to retinal detachment, atrophy and vision loss.
MicroStatTM is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (eye dilation). Almost everyone who has had an eye examination has been treated with these drugs – there are more than 80 million topical applications performed every year in the US. Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, by reducing the number of doses in half and minimizing dose-related side effects (including the need to wipe away excess drug that may fall out of the eye).
US 80M eye exams
Chronic Angle Closure Glaucoma
Reduction of Intraocular Pressure in Chronic Angle Closure Glaucoma (CACG), Open Angle Glaucoma (OAG) and Ocular Hypertension (OHT)
MicroProstTM is our proprietary prostaglandin microdose formulation and candidate for the first-line treatment of CACG, OAG and OHT. Currently there are no prostaglandins approved by the FDA for CACG, which accounts for 10% of all glaucoma diagnoses in the US and up to half of all in China. An approval would make MicroProst the first prostaglandin to cover all three types of patients.
CACG is a chronic disease in which most of the 580,000+ patients in the US will require life-long therapy to lower their intraocular pressure and reduce the risk of disease progression.
Similar to open-angle glaucoma, angle-closure glaucoma is characterized by increased intraocular pressure leading to optic nerve damage and vision loss.
MicroTears for Red Eye Relief / Lubrication
MicroTears™ is our differentiated micro-dose red eye reliever and ocular lubricant for the $850 million US ocular OTC market. Red eyes is a common condition that occurs in almost all adults, especially with increasing screen-time and lack of sleep. Our technology may help these patients treat episodes of red eye and ocular dryness more effectively by providing proven ingredients that, when micro-dosed, may have long-term efficacy and tolerability advantages over traditional eye drops. Additionally by using the Optejet™ patients may experience an easier, faster and neater method of instilling drops than “flooding” the eye with today’s methods.